One Brave Idea

One Brave Idea is a collaborative research enterprise focused on revolutionizing the detection and prevention of coronary heart disease. Established through a $75 million investment from the American Heart Association, Verily Life Sciences, and AstraZeneca, the initiative seeks to identify the earliest biological triggers of cardiovascular disease. The organization utilizes a multidisciplinary approach, combining clinical medicine, engineering, and data science to develop new diagnostic tools and therapeutic strategies. Based at Brigham and Women's Hospital, One Brave Idea aims to move beyond traditional risk factors to create a comprehensive map of disease progression. Their ultimate goal is to enable personalized, preventative care that stops heart disease before it starts.